http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0673650-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4655b70cbfba352025a1d2393b449e77
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4816
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02
filingDate 1995-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4573971f8ceeda44ecd10265d3f4b0f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cafd8fc050b8d70a3969df8163c7c5e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fba466aa29b2ca1a0ed87b653ec4d2c
publicationDate 1995-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0673650-A1
titleOfInvention Pharmaceutical sustained-release dosage forms containing alfusozine hydrochloride
abstract Pharmaceutical forms with targeted release of alfuzosin hydrochloride, comprising a core containing the active principle covered with a coating containing a polymer with pH-dependent dissolution. Application to the preparation of extended-release dosage forms, usable for oral administration once a day.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AP-1107-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2752737-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1937223-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0799619-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6177430-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9808515-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0799619-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1937223-A1
priorityDate 1994-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0204597-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4315007-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535626
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226401602
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415887923
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452282177
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID228879
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454362367
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65358
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449757623
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2092
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6917
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24832091
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426260387
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25137863
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21862903

Total number of triples: 58.